Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > Statistical analysis and Bucillamine

<< Previous

Bullboard Posts

Next >>

Comment by Hydroqcon May 03, 2021 11:07pm

176 Views

Post# 33121257

RE:Statistical analysis and Bucillamine

As for today annoncement of the research agreement whith UCSF, don't forget RVV has a IRB approval since 16 sept 2020 for the severe case, so they must have some data that are not on held hostage by our phase 3 trial.

https://www.globenewswire.com/fr/news-release/2020/09/16/2094472/0/en/Revive-Therapeutics-Announces-IRB-Approval-of-US-Expanded-Access-Treatment-Program-Compassionate-Use-for-Bucillamine-in-COVID-19.html?fbclid=IwAR3haqhDYovCPVksiAigeoS_ipWcQVmJbY7_c__HOgd_K7yTHE1yEQVOsDY